Skip to main content
Top
Published in: Clinical Research in Cardiology 6/2010

Open Access 01-06-2010 | Clinical Trial Updates and Hotline Sessions

Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more

Authors: C. Jacobshagen, D. Westermann, C. Holubarsch, M. Böhm

Published in: Clinical Research in Cardiology | Issue 6/2010

Login to get access

Abstract

This article gives an overview on a number of novel clinical trials in the field of cardiovascular medicine, which were presented during the Late Breaking Clinical Trial Sessions at the 59th annual meeting of the American College of Cardiology in Atlanta, USA, from 14th March to 16th March 2010. The data were presented by leading experts in the field with relevant positions in the trials. These comprehensive summaries should provide the readers with the most recent data on diagnostic and therapeutic developments in cardiovascular medicine similar as previously reported (Schirmer SH, van der Laan AM, Bohm M, Mahfoud F in Clin Res Cardiol 98:691–699, 2009; Maier LS, Schirmer SH, Walenta K, Jacobshagen C, Bohm M in Clin Res Cardiol 98:413–419, 2009).
Literature
1.
go back to reference Schirmer SH, van der Laan AM, Bohm M, Mahfoud F (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98:691–699CrossRefPubMed Schirmer SH, van der Laan AM, Bohm M, Mahfoud F (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98:691–699CrossRefPubMed
2.
go back to reference Maier LS, Schirmer SH, Walenta K, Jacobshagen C, Bohm M (2009) Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009. Clin Res Cardiol 98:413–419CrossRefPubMed Maier LS, Schirmer SH, Walenta K, Jacobshagen C, Bohm M (2009) Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009. Clin Res Cardiol 98:413–419CrossRefPubMed
3.
go back to reference The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358:2545–2559CrossRef The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 358:2545–2559CrossRef
4.
go back to reference The ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med [Epub ahead of print] The ACCORD Study Group (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med [Epub ahead of print]
5.
go back to reference The ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med [Epub ahead of print] The ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med [Epub ahead of print]
6.
go back to reference MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765–774CrossRefPubMed MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J (1990) Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335:765–774CrossRefPubMed
7.
go back to reference Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665CrossRefPubMed Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665CrossRefPubMed
8.
go back to reference The NAVIGATOR Study Group (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med [Epub ahead of print] The NAVIGATOR Study Group (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med [Epub ahead of print]
9.
go back to reference The NAVIGATOR Study Group (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med [Epub ahead of print] The NAVIGATOR Study Group (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med [Epub ahead of print]
10.
go back to reference Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003CrossRefPubMed Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H (2002) Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003CrossRefPubMed
11.
go back to reference Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031CrossRefPubMed Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031CrossRefPubMed
12.
go back to reference Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, van Veldhuisen DJ, Van den Berg MP (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med [Epub ahead of print] Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, van Veldhuisen DJ, Van den Berg MP (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med [Epub ahead of print]
13.
go back to reference Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Thuesen L, Lassen JF (2010) Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet [Epub ahead of print] Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, Abildgaard U, Christiansen EH, Engstrom T, Krusell LR, Ravkilde J, Hansen PR, Hansen KN, Abildstrom SZ, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Madsen M, Johnsen SP, Jensen LO, Sorensen HT, Thuesen L, Lassen JF (2010) Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet [Epub ahead of print]
14.
go back to reference Capodanno D, Capranzano P, Bucalo R, Sanfilippo A, Ruperto C, Caggegi A, Ussia G, Galassi AR, Tamburino C (2009) A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. Clin Res Cardiol 98:240–248CrossRefPubMed Capodanno D, Capranzano P, Bucalo R, Sanfilippo A, Ruperto C, Caggegi A, Ussia G, Galassi AR, Tamburino C (2009) A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score. Clin Res Cardiol 98:240–248CrossRefPubMed
15.
go back to reference Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010) Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med [Epub ahead of print] Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010) Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med [Epub ahead of print]
16.
go back to reference Gorelik O, moznino-Sarafian D, Shteinshnaider M, Alon I, Tzur I, Sokolsky I, Efrati S, Babakin Z, Modai D, Cohen N (2009) Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. Clin Res Cardiol 98:224–232CrossRefPubMed Gorelik O, moznino-Sarafian D, Shteinshnaider M, Alon I, Tzur I, Sokolsky I, Efrati S, Babakin Z, Modai D, Cohen N (2009) Clinical variables affecting survival in patients with decompensated diastolic versus systolic heart failure. Clin Res Cardiol 98:224–232CrossRefPubMed
17.
go back to reference Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553CrossRefPubMed Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553CrossRefPubMed
18.
go back to reference Maier LS, Baumhakel M, Bohm M (2009) Hotline sessions presented at the American College of Cardiology Congress 2009. Clin Res Cardiol 98:345–352CrossRefPubMed Maier LS, Baumhakel M, Bohm M (2009) Hotline sessions presented at the American College of Cardiology Congress 2009. Clin Res Cardiol 98:345–352CrossRefPubMed
Metadata
Title
Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more
Authors
C. Jacobshagen
D. Westermann
C. Holubarsch
M. Böhm
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 6/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0154-6

Other articles of this Issue 6/2010

Clinical Research in Cardiology 6/2010 Go to the issue